
Asst Prof| Medical Oncologist| Medical Educator| @annualsdui SDUI 2017-2020|๐ธ๐ฉ๐ฎ๐ช
Dublin , Ireland
Joined April 2018
- Tweets3K
- Following302
- Followers515
- Likes3.7K
Some call us Arabs, some call us Africans, and some call us Afro-arab... Being Sudanese is not about ethnicity, it's all about the values that we embrace, love we share, ethics and values embroided to our souls.
#SudanProtests
#SudanUprising
#ุงูุณูุฏุงู โ at Khartoum, Sudan
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
Leaving beautiful Madrid with renewed energy and enthusiasm!
Amazing conversations, reunions, practice-changing data, and art!
#ESMO26 @OncoAlert
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
These Kaplan-Meier curves finally separateโฆ by about the width of a pixel...
The curves ride on top of each other for years before a modest late subatomic divergence, and then the blue arm takes a dramatic vertical plunge at the far righ, right about the time the numbers at risk collapse to single digits. Truly a triumph of statistical significance over clinical drama.
Novartis is already calling a ~20% relative reduction โclinically meaningful.โ Somewhere a health economist is quietly calculating the cost per life-year for treating 5,100 patients to avert ~27 deaths.@5_utr
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
INTerpath-001 - the result of decades of scientific advances and research led to this moment! And brilliant delivery by @ProfGLongMIA
Personalized mRNA vaccines + Pembro as adjuvant trt improve RFS for pts with resects IIB-IV Melanoma!!
Important points:
Tox: a significant number of adverse events occurred BEFORE the vaccine was started
Access: the vaccines was given globally
#ESMO26 @OncoAlert
๐ก๏ธThe First Personalised mRNA Vaccine Shows Spectacular Results in Melanoma. Phase 3 INTerpath-001 trial evaluated the first-in-class personalised mRNA vaccine Intismeran autogene (mRNA-4157/V940) combined with Pembrolizumab in resected high-risk Stage IIB-IV melanoma.
๐RFS at 24 months was 82.2% vs 70.0% with pembrolizumab alone (HR 0.58; p<0.001).
๐42% reduction in the risk of recurrence or death.
๐INTerpath-001 sets a new benchmark for adjuvant therapy in melanoma.
We are moving from "one-size-fits-all" treatments to individualised, bespoke immunotherapy
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
#ESMO26 ๐ RASolute 302 | Phase III
๐ฅ 500 pts | Previously treated mPDAC
๐ Daraxonrasib (RAS(ON) inhibitor) vs chemo
๐ OS: 13.2 vs 6.7 mo (HR 0.40)
๐งฌ OS benefit by RAS genotype:
๐น G12D: HR 0.49
๐น G12V: HR 0.32
๐น G12R: HR 0.61
๐ PFS: HR 0.55 (BICR)
๐ฏ ORR: 32% vs 11%
๐ก new SOC!
@OncoAlert
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
There is an allegation that a journal editor demanded a $300K bribe to publish a manuscript.
This editor used to work at Science and now is editor in chief of a top cancer journal.
There is no doubt a very shady business that surrounds academic publishing, sustained by rent seekers throughout the biomedical system. Institutions have attached enormous rewards to getting through a journalโs gate while paying far less attention to who controls that gate and how the decisions are made.
A major problem in academic research is how much judgment has been outsourced to journal names and the editors who control access to them.
Professional journal editors are former scientists who left research for a more straightforward job, often paying far less than a faculty position or a job in industry. Yet universities and scientific organizations have given these editors tremendous power over careers and the allocation of hundreds of billions of dollars.
As the biomedical system expanded and became more compartmentalized, there were too many scientists and laboratories for people evaluating them to assess everyoneโs work themselves. The journalโs name became a substitute for judging the science. Where something was published determined what it was worth.
That judgment carries enormous financial consequences. Academic rank and stature depend on it. Venture capitalists use the journalโs name to reduce the perceived risk of investments. Pharma directs its attention toward those publications. Universities use them to select people for administrative positions, some carrying seven-figure salaries. Having your name on the right papers can open those doors even if the papers were completely wrong to begin with.
A Cancer Cell paper can be worth far more than $300K. An author can use it to raise many times that amount from investors and start a biotech company. The financial value attached to the publications a single editor decides to accept could approach a billion dollars while that editor makes $80K.
Meanwhile, almost no attention is paid to how qualified these individuals are to make such consequential scientific assessments, why they have been given so much authority, or why their compensation is so low relative to the financial interests surrounding their decisions. That disparity creates opportunities for impropriety.
However, this remains an allegation, and the editor is innocent until proven guilty.
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
So this is a wow. The control arm isn't current SOC but
HR for PFS and OS are SOLO1 level. Cheesus this changes things ..... businesswire.com/news/home/2โฆ
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
๐#ESMO26 Proffered Paper: #LCSM Non-Mets
๐ฅASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer
๐๏ธ @drgandara
๐ข3809O
๐ฏSerplulimab Numerically Longer OS vs Atezolizumab
๐ฏmOS 12.4 vs 10.2m, HR 0.82; 24-Mo OS 32.2% vs 17.6%
โ๏ธNCT05468489
๐ cslide.ctimeetingtech.com/esโฆ
@OncoAlert @Larvol @myESMO @IASLC
๐ #ESMO26 Proffered Paper: #LCSM Non-Mets NSCLC, others
๐ฅASTRIDE: Randomized Trial of Serplulimab or Atezolizumab Plus Chemotherapy in USA Patients With Extensive-Stage Small Cell Lung Cancer
๐๏ธ @drgandara
๐ข3809O
๐ cslide.ctimeetingtech.com/esโฆ
โ๏ธNCT05468489
@OncoAlert @Larvol @myESMO @IASLC
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
Evidence in NCCN Harmonized Guidelines for Sub-Saharan Africa: A Meta-Research Analysis.
Read the full article. bit.ly/3VRZA4r
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
The session โAccessible cancer care for everyone, everywhere: Improving patient care globallyโ explores challenges and solutions to improve equitable access, affordability and availability of cancer medicines worldwide.
โก๏ธcslide.ctimeetingtech.com/esโฆ
#ESMO26
@darioT_ @anmwongNZ
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
Great to share some thoughts on โMentorship 101โ at the #AILCC26 ๐ฎ๐ช
One concept I wanted to highlight: hedonic adaptation or โbecoming accustomed to successโ
Yesterdayโs dream becomes todayโs normality and tomorrowโs expectations.
In medicine, we constantly chase the next publication, grant, promotion or achievement. But do we ever stop to appreciate how far weโve come?
We guide a d help our mentees on how to be successful. How about guiding them on how to feel successful? @DrJNaidoo @FordePatrick @gerryhanna
#Mentorship #MedicalEducation #Leadership
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
Exploring the immunological effects of antibodyโdrug conjugates
nature.com/articles/s41571-0โฆ
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
Are you heading to #ESMO26 in Madrid? Donโt forget to attend the ESMO-MCBS special session on Friday afternoon! @oncology_bg will talk on how to read a clinical trial! cslide.ctimeetingtech.com/esโฆ
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
๐Excited to share our publication evaluating TP53 alterations with a closer look at TP53 Y220C alteration in metastatic breast cancer @JCOOA_ASCO
ascopubs.org/doi/10.1200/OA-โฆ
@YaleBreast @YaleCancer @FoundationATCG @maryam_lustberg @AdrianaKahnMD
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
Advances in Systemic Treatment of Breast Cancer | New England Journal of Medicine nejm.org/doi/full/10.1056/NEโฆ Excellent review @NEJM @OncoAlert
Presented at #IGCS2026: Our structured needs assessment on Gynecologic Oncology capacity in Sudan post-armed conflict (14 facilities across 10 states):
โข Brachytherapy unavailable across all surveyed sites
โข Radiation wait times >5โ8 weeks where referrals exist
โข Screening absent in 79% of centers
Internally displaced persons comprise up to 50% of the patient volume at receiving peripheral centers, alongside severe deficits in surgical oncology workforce and basic palliative care (oral morphine).
Targeted global oncology support is urgent.
โ๐ shorturl.at/RE7To
@IGCSociety
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
This randomized trial examined whether adding a multicancer early-detection blood test to usual care reduces late-stage cancer diagnoses in adults 50 to 77 years of age. Research findings from the NHS-Galleri trial are summarized in a new Quick Take video. nej.md/4iZFheW
How should we govern AI in health professions education?
1/5 AI in health professions education is not just a technology question. It is a question of governance, ethics, academic integrity, equity and professional identity.
Our critical narrative review examines these challenges.
๐ shorturl.at/V450L
2/5 First: governance. Institutional responses may be fragmented, while educational applications of AI continue to evolve.
How can policies remain useful without becoming quickly outdated?
3/5 Second: ethics. AI raises difficult questions about autonomy, beneficence, non-maleficence and justiceโparticularly when systems are opaque or data-driven.
4/5 Third and fourth: generative AI challenges established ideas of authorship and academic integrity, while bias and unequal access raise concerns about equity and professional development.
5/5 Responsible AI in medical education needs more than a blanket โallowโ or โban.โ
Our review proposes a risk-based governance taxonomy. What should institutions prioritise first: transparency, assessment integrity, fairness or accountability?
#MedicalEducation #AIethics
๐จ๐ช๐ผ๐ช๐ป ๐๐ช๐ถ๐ถ๐ธ๐ป retweeted
Use of Vaginal Estrogen in Breast and Gynecologic Cancer Survivors | JCO Oncology Practice ascopubs.org/doi/10.1200/OP-โฆ @OncoAlert @JCOOP_ASCO @MMAlHilli @ClevelandClinic in selected patients with refractory symptoms low dose vaginal estrogen could be effective !













































